Atea Pharmaceuticals (AVIR)
(Delayed Data from NSDQ)
$3.52 USD
-0.01 (-0.28%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $3.52 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AVIR 3.52 -0.01(-0.28%)
Will AVIR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AVIR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVIR
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
AVIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised
Transplant Logistic Service Business Likely to Aid TMDX's Q3 Earnings
Other News for AVIR
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update ...
Atea Pharmaceuticals (AVIR) Launches Phase 3 Trial for Hepatitis C Treatment | AVIR Stock News
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing ...
Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial
Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial